A comprehensive diagnostic approach to detect underlying causes of obesity in adults

Eline S van der Valk, Erica L T van den Akker, Mesut Savas, Lotte Kleinendorst, Jenny A Visser, Mieke M Van Haelst, Arya M Sharma, Elisabeth F C van Rossum, Eline S van der Valk, Erica L T van den Akker, Mesut Savas, Lotte Kleinendorst, Jenny A Visser, Mieke M Van Haelst, Arya M Sharma, Elisabeth F C van Rossum

Abstract

Obesity is a worldwide growing problem. When confronted with obesity, many health care providers focus on direct treatment of the consequences of adiposity. We plead for adequate diagnostics first, followed by an individualized treatment. We provide experience-based and evidence-based practical recommendations (illustrated by clinical examples), to detect potential underlying diseases and contributing factors. Adult patients consulting a doctor for weight gain or obesity should first be clinically assessed for underlying diseases, such as monogenetic or syndromic obesity, hypothyroidism, (cyclic) Cushing syndrome, polycystic ovarian syndrome (PCOS), hypogonadism, growth hormone deficiency, and hypothalamic obesity. The most important alarm symptoms for genetic obesity are early onset obesity, dysmorphic features/congenital malformations with or without intellectual deficit, behavioral problems, hyperphagia, and/or striking family history. Importantly, also common contributing factors to weight gain should be investigated, including medication (mainly psychiatric drugs, (local) corticosteroids, insulin, and specific β-adrenergic receptor blockers), sleeping habits and quality, crash diets and yoyo-effect, smoking cessation, and alcoholism. Other associated conditions include mental factors such as chronic stress or binge-eating disorder and depression.Identifying and optimizing the underlying diseases, contributing factors, and other associated conditions may not only result in more effective and personalized treatment but could also reduce the social stigma for patients with obesity.

Keywords: Diagnostics; genetic obesity; hormones; medication; secondary causes.

© 2019 The Authors. Obesity Reviews published by John Wiley & Sons Ltd on behalf of World Obesity Federation.

Figures

Figure 1
Figure 1
Recognizing underlying causes of obesity in adults. ADD, attention deficit disorder; PCOS, polycystic ovarian syndrome; MC4R, melanocortin 4 receptor; POMC, proopiomelanocortin; PPI, proton pump inhibitors; OC, oral contraceptives; OSA, obstructive sleep apnea; OSFED, other specified feeding and eating disorders [Colour figure can be viewed at http://wileyonlinelibrary.com]

References

    1. Bray GA, Kim KK, Wilding JPH, World OF. Obesity: a chronic relapsing progressive disease process. A position statement of the World obesity federation. Obes Rev. 2017;18(7):715‐723.
    1. World Health Organisation . Obesity and Overweight fact sheet. june 2016 2016.
    1. Collaborators GBDO . Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017;377:13‐17.
    1. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Hypertension. 2018;71(6):e13‐e115.
    1. Yumuk V, Tsigos C, Fried M, et al. European guidelines for obesity management in adults. Obes Facts. 2015;8(6):402‐424.
    1. Garvey WT, Mechanick JI, Brett EM, et al. American Association of Clinical Endocrinologists and American College of endocrinology comprehensive clinical practice guidelines for medical Care of Patients with obesity. Endocr Pract. 2016;22(Suppl 3):1‐203.
    1. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the Obesity Society. Circulation. 2014;129(25 Suppl 2):S102‐S138.
    1. Saad F, Yassin A, Doros G, Haider A. Effects of long‐term treatment with testosterone on weight and waist size in 411 hypogonadal men with obesity classes I‐III: observational data from two registry studies. Int J Obes (Lond). 2016;40(1):162‐170.
    1. Biondi B. Thyroid and obesity: an intriguing relationship. J Clin Endocrinol Metab. 2010;95(8):3614‐3617.
    1. Sanyal D, Raychaudhuri M. Hypothyroidism and obesity: an intriguing link. Indian J Endocrinol Metab. 2016;20(4):554‐557.
    1. Hainerova IA, Lebl J. Treatment options for children with monogenic forms of obesity. World Rev Nutr Diet. 2013;106:105‐112.
    1. Alsters S. Genetic Analysis of Extreme Obesity. London: Department of Medicine, Imperial College London; 2016.
    1. Fani L, Bak S, Delhanty P, van Rossum EF, van den Akker EL. The melanocortin‐4 receptor as target for obesity treatment: a systematic review of emerging pharmacological therapeutic options. Int J Obes (Lond). 2014;38(2):163‐169.
    1. Kühnen P, Clément K, Wiegand S, et al. Proopiomelanocortin deficiency treated with a melanocortin‐4 receptor agonist. N Engl J Med. 2016;375(3):240‐246.
    1. Sharma AM, Padwal R. Obesity is a sign―over‐eating is a symptom: an aetiological framework for the assessment and management of obesity. Obes Rev. 2010;11(5):362‐370.
    1. Romieu I, Dossus L, Barquera S, et al. Energy balance and obesity: what are the main drivers? Cancer Causes Control. 2017;28(3):247‐258.
    1. Heymsfield SB, Harp JB, Reitman ML, et al. Why do obese patients not lose more weight when treated with low‐calorie diets? A mechanistic perspective. Am J Clin Nutr. 2007;85(2):346‐354.
    1. Macht M. How emotions affect eating: a five‐way model. Appetite. 2008;50(1):1‐11.
    1. Cappuccio FP, Taggart FM, Kandala NB, et al. Meta‐analysis of short sleep duration and obesity in children and adults. Sleep. 2008;31(5):619‐626.
    1. Patel SR, Hu FB. Short sleep duration and weight gain: a systematic review. Obesity (Silver Spring). 2008;16(3):643‐653.
    1. Bayon V, Leger D, Gomez‐Merino D, Vecchierini MF, Chennaoui M. Sleep debt and obesity. Ann Med. 2014;46(5):264‐272.
    1. Minkel J, Moreta M, Muto J, et al. Sleep deprivation potentiates HPA axis stress reactivity in healthy adults. Health Psychol. 2014;33(11):1430‐1434.
    1. Manenschijn L, Van Kruysbergen RG, De Jong FH, Koper JW, Lamberts SWJ, Van Rossum EFC. Shift work at young age is associated with elevated long‐term cortisol levels and body mass index. Endocr Rev. 2012;33(3):E1862‐E1865.
    1. van der Valk ES, Savas M, van Rossum EFC. Stress and obesity: are there more susceptible individuals? Curr Obes Rep. 2018;7(2):193‐203.
    1. Broussard JL, Van Cauter E. Disturbances of sleep and circadian rhythms: novel risk factors for obesity. Curr Opin Endocrinol Diabetes Obes. 2016;23(5):353‐359.
    1. McHill AW, Wright KP Jr. Role of sleep and circadian disruption on energy expenditure and in metabolic predisposition to human obesity and metabolic disease. Obes Rev. 2017;18(Suppl 1):15‐24.
    1. St‐Onge MP, Shechter A. Sleep disturbances, body fat distribution, food intake and/or energy expenditure: pathophysiological aspects. Horm Mol Biol Clin Invest. 2014;17(1):29‐37.
    1. Shechter A. Effects of continuous positive airway pressure on energy balance regulation: a systematic review. Eur Respir J. 2016;48(6):1640‐1657.
    1. Shechter A. Obstructive sleep apnea and energy balance regulation: a systematic review. Sleep Med Rev. 2017;34:59‐69.
    1. Drager LF, Brunoni AR, Jenner R, Lorenzi‐Filho G, Bensenor IM, Lotufo PA. Effects of CPAP on body weight in patients with obstructive sleep apnoea: a meta‐analysis of randomised trials. Thorax. 2015;70(3):258‐264.
    1. Nymo S, Coutinho SR, Torgersen LH, et al. Timeline of changes in adaptive physiological responses, at the level of energy expenditure, with progressive weight loss. Br J Nutr. 2018;120(2):141‐149.
    1. Myers A, Gibbons C, Finlayson G, Blundell J. Associations among sedentary and active behaviours, body fat and appetite dysregulation: investigating the myth of physical inactivity and obesity. Br J Sports Med. 2017;51(21):1540‐1544.
    1. Villablanca PA, Alegria JR, Mookadam F, Holmes DR Jr, Wright RS, Levine JA. Nonexercise activity thermogenesis in obesity management. Mayo Clin Proc. 2015;90(4):509‐519.
    1. Kim SH, Plutzky J. Brown fat and browning for the treatment of obesity and related metabolic disorders. Diabetes Metab J. 2016;40(1):12‐21.
    1. Yoneshiro T, Aita S, Matsushita M, et al. Recruited brown adipose tissue as an antiobesity agent in humans. J Clin Invest. 2013;123(8):3404‐3408.
    1. Harris KK, Zopey M, Friedman TC. Metabolic effects of smoking cessation. Nat Rev Endocrinol. 2016;12(5):299‐308.
    1. Bush T, Lovejoy JC, Deprey M, Carpenter KM. The effect of tobacco cessation on weight gain, obesity, and diabetes risk. Obesity (Silver Spring). 2016;24(9):1834‐1841.
    1. Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(2):342‐362.
    1. Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta‐analysis. J Clin Psychiatry. 2010;71(10):1259‐1272.
    1. Allison DB, Casey DE. Antipsychotic‐induced weight gain: a review of the literature. J Clin Psychiatry. 2001;62(Suppl 7):22‐31.
    1. Da Silva JAP, Jacobs JWG, Kirwan JR, et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis. 2006;65(3):285‐293.
    1. Savas M, Muka T, Wester VL, et al. Associations between systemic and local corticosteroid use with metabolic syndrome and body mass index. J Clin Endocrinol Metab. 2017;102(10):3765‐3774.
    1. Broersen LH, Pereira AM, Jorgensen JO, Dekkers OM. Adrenal insufficiency in corticosteroids use: systematic review and meta‐analysis. J Clin Endocrinol Metab. 2015;100(6):2171‐2180.
    1. Sharma AM, Pischon T, Hardt S, Kunz I, Luft FC. Hypothesis: beta‐adrenergic receptor blockers and weight gain: a systematic analysis. Hypertension. 2001;37(2):250‐254.
    1. Messerli FH, Bell DS, Fonseca V, et al. Body weight changes with beta‐blocker use: results from GEMINI. Am J Med. 2007;120(7):610‐615.
    1. Manrique C, Whaley‐Connell A, Sowers JR. Nebivolol in obese and non‐obese hypertensive patients. J Clin Hypertens (Greenwich). 2009;11(6):309‐315.
    1. Ratliff JC, Barber JA, Palmese LB, Reutenauer EL, Tek C. Association of prescription H1 antihistamine use with obesity: results from the National Health and nutrition examination survey. Obesity (Silver Spring). 2010;18(12):2398‐2400.
    1. Gallo MF, Lopez LM, Grimes DA, Carayon F, Schulz KF, Helmerhorst FM. Combination contraceptives: effects on weight. Cochrane Database Syst Rev. 2014;1 CD003987. 10.1002/14651858.CD003987.pub5
    1. Cheskin LJ, Bartlett SJ, Zayas R, Twilley CH, Allison DB, Contoreggi C. Prescription medications: a modifiable contributor to obesity. South Med J. 1999;92(9):898‐904.
    1. Yoshikawa I, Nagato M, Yamasaki M, Kume K, Otsuki M. Long‐term treatment with proton pump inhibitor is associated with undesired weight gain. World J Gastroenterol. 2009;15(38):4794‐4798.
    1. Ehrlich AC, Friedenberg FK. Genetic associations of obesity: the fat‐mass and obesity‐associated (FTO) gene. Clin Transl Gastroenterol. 2016;7(1):e140.
    1. Bays H, Scinta W. Adiposopathy and epigenetics: an introduction to obesity as a transgenerational disease. Curr Med Res Opin. 2015;31(11):2059‐2069.
    1. Kleinendorst L, Massink MPG, Cooiman MI, et al. Genetic obesity: next‐generation sequencing results of 1230 patients with obesity. J Med Genet. 2018;55(9):578‐586.
    1. Farooqi IS. The severely obese patient—a genetic work‐up. Nat Clin Pract Endocrinol Metab. 2006;2(3):172‐177.
    1. Styne DM, Arslanian SA, Connor EL, et al. Pediatric obesity—assessment, treatment, and prevention: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metabol. 2017;102(6):2123‐2124.
    1. Holm VA, Cassidy SB, Butler MG, et al. Prader‐Willi syndrome: consensus diagnostic criteria. Pediatrics. 1993;91(2):398‐402.
    1. Miller DT, Chung W, Nasir R. 16p11.2 Recurrent Microdeletion In: Pagon RA, Adam MP, Ardinger HH, et al., eds. GeneReviews®. WA: University of Washington, Seattle; 2015. [Updated 2015 Dec 10] ed.
    1. Haldeman‐Englert CR, Hurst ACE, Levine MA. Disorders of GNAS Inactivation. 1993.
    1. Farooqi IS, Keogh JM, Yeo GS, Lank EJ, Cheetham T, O'Rahilly S. Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N Engl J Med. 2003;348(12):1085‐1095.
    1. Laurberg P, Knudsen N, Andersen S, Carle A, Pedersen IB, Karmisholt J. Thyroid function and obesity. Eur Thyroid J. 2012;1(3):159‐167.
    1. Reinehr T, de Sousa G, Andler W. Hyperthyrotropinemia in obese children is reversible after weight loss and is not related to lipids. J Clin Endocrinol Metab. 2006;91(8):3088‐3091.
    1. Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing's syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2008;93(5):1526‐1540.
    1. Savas M, Wester VL, Staufenbiel SM, et al. Systematic evaluation of corticosteroid use in obese and non‐obese individuals: a multi‐cohort study. Int J Med Sci. 2017;14(7):615‐621.
    1. Savas MMT, Wester VL, van den Akker ELT, et al. Associations between systemic and local corticosteroid use with metabolic syndrome and body mass index. J Clin Endocrinol Metabol. 2017;102(10):3765‐3774.
    1. Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol. 2006;154(6):899‐906.
    1. Corona G, Rastrelli G, Monami M, et al. Body weight loss reverts obesity‐associated hypogonadotropic hypogonadism: a systematic review and meta‐analysis. Eur J Endocrinol. 2013;168(6):829‐843.
    1. Gunderson EP, Sternfeld B, Wellons MF, et al. Childbearing may increase visceral adipose tissue independent of overall increase in body fat. Obesity (Silver Spring). 2008;16(5):1078‐1084.
    1. Sowers M, Zheng H, Tomey K, et al. Changes in body composition in women over six years at midlife: ovarian and chronological aging. J Clin Endocrinol Metab. 2007;92(3):895‐901.
    1. Gunderson EP. Childbearing and obesity in women: weight before, during, and after pregnancy. Obstet Gynecol Clin North Am. 2009;36(2):317‐332. ix
    1. Davis SR, Castelo‐Branco C, Chedraui P, et al. Understanding weight gain at menopause. Climacteric. 2012;15(5):419‐429.
    1. Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML, Endocrine S. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(6):1587‐1609.
    1. Maison P, Griffin S, Nicoue‐Beglah M, et al. Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH‐deficient adults: a metaanalysis of blinded, randomized, placebo‐controlled trials. J Clin Endocrinol Metab. 2004;89(5):2192‐2199.
    1. Cenci MC, Conceicao FL, Soares DV, et al. Impact of 5 years of growth hormone replacement therapy on cardiovascular risk factors in growth hormone‐deficient adults. Metabolism. 2008;57(1):121‐129.
    1. Bereket A, Kiess W, Lustig RH, et al. Hypothalamic obesity in children. Obes Rev. 2012;13(9):780‐798.
    1. Lee M, Korner J. Review of physiology, clinical manifestations, and management of hypothalamic obesity in humans. Pituitary. 2009;12(2):87‐95.
    1. Faith MS, Butryn M, Wadden TA, Fabricatore A, Nguyen AM, Heymsfield SB. Evidence for prospective associations among depression and obesity in population‐based studies. Obes Rev. 2011;12(5):e438‐e453.
    1. de Wit L, Luppino F, van Straten A, Penninx B, Zitman F, Cuijpers P. Depression and obesity: a meta‐analysis of community‐based studies. Psychiatry Res. 2010;178(2):230‐235.
    1. Milaneschi Y, Simmons WK, van Rossum EFC, Penninx BW. Depression and obesity: evidence of shared biological mechanisms. Mol Psychiatry. 2018;24:18‐38.
    1. Association AP . Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington DC: American Psychiatric Association; 2013.
    1. Rajan TM, Menon V. Psychiatric disorders and obesity: a review of association studies. J Postgrad Med. 2017;63(3):182‐190.
    1. Hudson JI, Hiripi E, Pope HG Jr, Kessler RC. The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication. Biol Psychiatry. 2007;61(3):348‐358.
    1. Dallman MF. Stress‐induced obesity and the emotional nervous system. Trends Endocrinol Metab. 2010;21(3):159‐165.
    1. Tamashiro KL, Sakai RR, Shively CA, Karatsoreos IN, Reagan LP. Chronic stress, metabolism, and metabolic syndrome. Stress. 2011;14(5):468‐474.
    1. Kiecolt‐Glaser JK, Fagundes CP, Andridge R, et al. Depression, daily stressors and inflammatory responses to high‐fat meals: when stress overrides healthier food choices. Mol Psychiatry. 2017;22(3):476‐482.
    1. Tomiyama AJ. Weight stigma is stressful. A review of evidence for the cyclic obesity/weight‐based stigma model. Appetite. 2014;82:8‐15.
    1. Fuemmeler BF, Dedert E, McClernon FJ, Beckham JC. Adverse childhood events are associated with obesity and disordered eating: results from a U.S. population‐based survey of young adults. J Trauma Stress. 2009;22(4):329‐333.
    1. Bergman Å, Heindel JJ, Jobling S, Kidd KA, Zoeller RT, Programme WHoatUNE . Endocrine Disrupting Chemicals. 2012.
    1. Darbre PD. Endocrine disruptors and obesity. Curr Obes Rep. 2017;6(1):18‐27.
    1. Qiao Y, Ma J, Wang Y, et al. Birth weight and childhood obesity: a 12‐country study. Int J Obes Suppl. 2015;5(Suppl 2):S74‐S79.
    1. Li DK, Chen H, Ferber J, Odouli R. Infection and antibiotic use in infancy and risk of childhood obesity: a longitudinal birth cohort study. Lancet Diabetes Endocrinol. 2017;5(1):18‐25.
    1. Xu MY, Cao B, Wang DF, et al. Human adenovirus 36 infection increased the risk of obesity: a meta‐analysis update. Medicine (Baltimore). 2015;94(51):e2357.
    1. Bouter KE, van Raalte DH, Groen AK, Nieuwdorp M. Role of the gut microbiome in the pathogenesis of obesity and obesity‐related metabolic dysfunction. Gastroenterology. 2017;152(7):1671‐1678.
    1. Wu FC, Tajar A, Beynon JM, et al. Identification of late‐onset hypogonadism in middle‐aged and elderly men. N Engl J Med. 2010;363(2):123‐135.
    1. Gafoor R, Booth HP, Gulliford MC. Antidepressant utilisation and incidence of weight gain during 10 years' follow‐up: population based cohort study. BMJ. 2018;361:k1951.
    1. Maayan L, Correll CU. Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol. 2011;21(6):517‐535.
    1. Medici V, McClave SA, Miller KR. Common medications which Lead to unintended alterations in weight gain or organ Lipotoxicity. Curr Gastroenterol Rep. 2016;18(1):2.
    1. Lampl Y, Eshel Y, Rapaport A, Sarova‐Pinhas I. Weight gain, increased appetite, and excessive food intake induced by carbamazepine. Clin Neuropharmacol. 1991;14(3):251‐255.
    1. Hodish I. Insulin therapy, weight gain and prognosis. Diabetes Obes Metab. 2018;20(9):2085‐2092.
    1. Hemmingsen B, Schroll JB, Wetterslev J, et al. Sulfonylurea versus metformin monotherapy in patients with type 2 diabetes: a Cochrane systematic review and meta‐analysis of randomized clinical trials and trial sequential analysis. CMAJ Open. 2014;2(3):E162‐E175.
    1. Bryson CM, Psaty BM. A review of the adverse effects of peripheral Alpha‐1 antagonists in hypertension therapy. Curr Control Trials Cardiovasc Med. 2002;3(1):7.
    1. Curtis JR, Westfall AO, Allison J, et al. Population‐based assessment of adverse events associated with long‐term glucocorticoid use. Arthritis Rheum. 2006;55(3):420‐426.
    1. Czwornog JL, Austin GL. Association of Proton Pump Inhibitor (PPI) use with energy intake, physical activity, and weight gain. Nutrients. 2015;7(10):8592‐8601.
    1. Ward EK, Jensen‐Otsu E, Schoen JA, Rothchild K, Mitchell B, Austin GL. Acid suppression medications are associated with suboptimal weight loss after laparoscopic roux‐en‐Y gastric bypass in patients older than 40 years. Surg Obes Relat Dis. 2015;11(3):585‐590.
    1. Anuurad E, Bremer A, Berglund L. HIV protease inhibitors and obesity. Curr Opin Endocrinol Diabetes Obes. 2010;17(5):478‐485.
    1. Willig AL, Overton ET. Metabolic complications and glucose metabolism in HIV infection: a review of the evidence. Curr HIV/AIDS Rep. 2016;13(5):289‐296.
    1. Huvenne H, Dubern B, Clement K, Poitou C. Rare genetic forms of obesity: clinical approach and current treatments in 2016. Obes Facts. 2016;9(3):158‐173.
    1. Cassidy SB, Driscoll DJ. Prader‐Willi syndrome. Eur J Hum Genet. 2009;17(1):3‐13.
    1. Forsythe E, Beales PL. Bardet‐Biedl syndrome. Eur J Hum Genet. 2013;21(1):8‐13.
    1. Dell'Edera D, Dilucca C, Allegretti A, et al. 16p11.2 microdeletion syndrome: a case report. J Med Case Reports. 2018;12(1):90.
    1. Martinelli CE, Keogh JM, Greenfield JR, et al. Obesity due to melanocortin 4 receptor (MC4R) deficiency is associated with increased linear growth and final height, fasting hyperinsulinemia, and incompletely suppressed growth hormone secretion. J Clin Endocrinol Metab. 2011;96(1):E181‐E188.
    1. Vollbach H, Brandt S, Lahr G, et al. Prevalence and phenotypic characterization of MC4R variants in a large pediatric cohort. Int J Obes (Lond). 2017;41(1):13‐22.
    1. Farooqi IS, Wangensteen T, Collins S, et al. Clinical and molecular genetic spectrum of congenital deficiency of the leptin receptor. N Engl J Med. 2007;356(3):237‐247.
    1. Krude H, Biebermann H, Gruters A. Mutations in the human proopiomelanocortin gene review. Ann N Y Acad Sci. 2003;994:233‐239.
    1. Ramos‐Molina B, Martin MG, Lindberg I. PCSK1 variants and human obesity. Prog Mol Biol Transl Sci. 2016;140:47‐74.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera